Time filter

Source Type

Foshan, China

He H.-Y.,Shantou University | Chen Z.-L.,Ophthalmic Center
International Eye Science | Year: 2015

Age-related macular degeneration (AMD) is one of the major reasons of blindness among the elderly in the developed countries. As AMD patients are increasing year by year, AMD has become one of the important topics of ophthalmic research to prevent blindness. Its pathogenesis is not fully understood, but many studies have shown that vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis. With the development and application of anti-VEGF drugs, there are a variety of drugs applied to the disease. This article introduces conbercept for the treatment of AMD. ©, 2015, International Journal of Ophthalmology (c/o Editorial Office). All right reserved. Source

Heiner P.,Vision Eye Institute | Ligabue E.,Ophthalmic Center | Fan A.,Chinese University of Hong Kong | Lam D.,Chinese University of Hong Kong
Clinical Ophthalmology | Year: 2014

Purpose: To evaluate the safety and effectiveness of a single-piece hydrophobic acrylic intraocular lens (IOL) (enVista ® MX60; Bausch and Lomb Incorporated, Rochester, NY, USA) following implantation to correct aphakia subsequent to extracapsular cataract extraction in adults. Subjects and methods: This was an open-label, non-interventional, observational study conducted in 19 university and private-practice settings in Europe and the Asia-Pacific region to investigate clinical outcomes of the MX60 IOL in standard practice. Eligible subjects were at least 18 years of age and had undergone standard phacoemulsification and extracapsular cataract extraction with implantation of the MX60 IOL. The primary safety endpoint was the occurrence of adverse events, and the primary effectiveness endpoints included visual and refractive outcomes and stability, with data collected up to 2 years post-procedure. Results: In this multicenter study, pooled data of 255 eyes were collected and analyzed. Excellent visual and refractive outcomes and stability were demonstrated. At postoperative visit 4 (61-180 days postoperative), 62.2% of subjects achieved a Snellen best-corrected distance visual acuity (CDVA) of 20/20 (decimal 1.00), and 97.8% of subjects achieved a CDVA of 20/40 (decimal 0.50) or better. One eye (1.0%) underwent neodymium:yttrium aluminum garnet capsulotomy at 12 months post-procedure. No glistenings of any grade were reported for any subject at any visit. Adverse events were infrequent and were consistent with incidences generally reported with cataract surgery. Conclusion: This study, which enrolled all comers, provided evidence of the excellent safety and effectiveness of the MX60 IOL in standard practice. Favorable clinical outcomes included outstanding visual and refractive outcomes and stability. No glistenings were reported at any postoperative visit. © 2014 Arora et al. Source

Luo S.,Ophthalmic Center | Lin Z.,Ophthalmic Center
Eye science | Year: 2012

PURPOSE: To investigate the stereopsis after single focus intraocular lens (SIOL) implantation in patients aged <40 years with unilateral cataract.METHODS: In total, 36 patients (36 eyes) were divided into emmetropia and myopia groups. Twenty seven subjects with good uncorrected distance visual acuity (UCDVA) after surgery were enrolled in the emmetropia group. The myopia group consisted of 9 subjects whose one eye had mild myopia postoperatively and the other was emmetropic or myopic. Visual acuity, distance and near stereoacuity were measured post-operatively.RESULTS: In the emmetropia group, uncorrected near visual acuity (UCNVA) did not differ significantly between eyes (t=1.87, P>0.05). The LogMAR UCNVA of the operated and fellow eyes were (0.71±0.12) and (-0.05±0.07, t = 28.4, P<0.001) respectively. Distance stereoacuity was 60"; the near stereoacuity with uncorrected visual acuity and BCNVA in the operated eyes were 200" and 30" respectively (Z=-4.121, P<0.001). In the myopia group, the BCDVA did not differ significantly between the operated and fellow eyes (t =-0.636, P>0.05). The UCNVA of the operated eyes (0.18±0.12) was significantly better compared with that of the fellow eyes (-0.04±0.10, t = 4.2252, P<0.001). The distance stereoacuity with uncorrected visual acuity and BCDVA in the operated eyes were 200" and 60" respectively (Z =-2.371, P<0.05). The near stereoacuity with uncorrected visual acuity was 50".CONCLUSION: For patients with unilateral cataract aged <40 years, stereopsis is closely associated with refractive status after IOL implantation. Near stereoacuity in emmetropic eyes can be improved with refraction, and that in mildly myopic eyes can be enhanced by leaving myopia uncorrected. Source

Guedes R.A.P.,Ophthalmic Center | Guedes R.A.P.,Federal University of Juiz de fora | Guedes V.M.P.,Ophthalmic Center | Guedes V.M.P.,Federal University of Juiz de fora | Chaoubah A.,Federal University of Juiz de fora
Ophthalmic Surgery Lasers and Imaging | Year: 2010

■ BACKGROUND AND OBJECTIVE: Phaco non-penetrating deep sclerectomy (PhacoNPDS) is an option to simultaneously treat cataract and glaucoma. The authors assessed tensional success of PhacoNPDS and NPDS up to 3 years of follow-up. ■ PATIENTS AND METHODS: A longitudinal consecutive retrospective study was conducted comparing 376 eyes undergoing NPDS (group 1) and 87 eyes undergoing PhacoNPDS (group 2). Success was defined as complete 1 (intraocular pressure [IOP] < 21 mm Hg without medication); complete 2 (at least a 20% reduction of preoperative IOP without medication), and qualified (IOP < 21 mm Hg with or without medication). ■ RESULTS: Preoperative IOP and number of medications were 23.7 and 2.7 in group 1 and 23.1 and 2.6 in group 2, respectively. Postoperative IOP (3 years) was 13.1 mm Hg in group 1 and 13.4 mm Hg in group 2 (P = .000). Complete 1, complete 2, and qualified success in 3 years were 57.5%, 53.7%, and 94.5% in group 1 and 56.1%, 56.1%, and 100% in group 2, respectively (P = .861, .772, and .159). Final number of medications was 0.5 in group 1 and 0.3 in group 2. ■ CONCLUSION: PhacoNPDS seems to achieve similar tensional results as NPDS alone up to 3 years of follow-up. Copyright ©SLACK Incorporated. Source

Zeng M.,Ophthalmic Center | Chen Z.-S.,Ophthalmic Center | Song Y.-P.,Ophthalmic Center
International Eye Science | Year: 2014

AIM: To compare the efficacy and safety of intravitreal ranibizumab to those of triamcinolone acetonide(TA) injection for the treatment of macular edema secondary to central retinal vein occlusion (CRVO). METHODS: This retrospective study included 40 eyes of 40 patients with macular edema associated with CRVO. Twenty patients 20 eyes were treated with intravitreal injection of triamcinolone acetonide (1mg, 0.1mL), the other 20 patients 20 eyes accepted intravitreal ranibizumab (0.5mg, 0.05mL). The change of best corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) before treatment and at 1, 2wk, 1, 2, 3, 6mo post-injection in the two groups were observed. RESULTS: BCVA was improved at 1, 2wk, 1, 2, 3, 6mo post-injection in the TA group (P<0.05) and ranibizumab group (P<0.05). No significant difference was found between the two groups (P>0.05). CMT decreased significantly within each group (P<0.05), and no significant difference between groups was found (P>0.05). In the TA group, the IOP was significantly higher at 2wk and 4wk than before treatment (P<0.05). In the ranibizumab group, no elevated IOP was observed at 1, 2wk, 1, 2, 3, 6mo (P>0.05). However, the IOP at 1mo was significantly higher in the TA group than that in the ranibizumb group (P<0.05). CONCLUSION: Intravitreal ranibizumab is an effective and safe treatment method for macular edema secondary to CRVO. It can effectively improve BCVA and reduce CMT without ocular and systemic complications compared with intravitreal TA. Source

Discover hidden collaborations